SCHEMBL4351146

SCHEMBL4351146

CC(C)(C)OC(=O)Sc1ccccn1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.44
EHMT2 Q96KQ7 1/20 0.42
EHMT1 Q9H9B1 1/20 0.42
APOBEC3G Q9HC16 1/20 0.42
ALDH1A1 P00352 5/20 0.41
RAB9A P51151 3/20 0.40
SMN1; SMN2 Q16637 4/20 0.40
HPGD P15428 3/20 0.40
HSD17B10 Q99714 2/20 0.40
KDM4E B2RXH2 1/20 0.40
NPC1 O15118 1/20 0.40
ALOX15 P16050 1/20 0.40
ELANE P08246 1/20 0.39
GPR119 Q8TDV5 1/20 0.39
KMT2A Q03164 2/20 0.39
MAPT P10636 1/20 0.39
MEN1 O00255 1/20 0.39
PKM P14618 1/20 0.39
POLB P06746 1/20 0.38
TSHR P16473 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2608495 0.81 LMNA (0.47) LMNAEHMT2EHMT1APOBEC3GALDH1A1
SCHEMBL28549513 0.79 MAPT (0.37) ALDH1A1RAB9ASMN1; SMN2HPGDNPC1
SCHEMBL14296134 0.77 EHMT2 (0.47) LMNAEHMT2EHMT1APOBEC3GALDH1A1
SCHEMBL19403428 0.76 LMNA (0.67) LMNAALDH1A1RAB9ASMN1; SMN2HPGD
SCHEMBL1343544 0.75 EHMT2 (0.44) LMNAEHMT2EHMT1APOBEC3GALDH1A1
SCHEMBL4757038 0.74 EHMT2 (0.52) LMNAEHMT2EHMT1APOBEC3GALDH1A1
SCHEMBL9900838 0.74 SMN1; SMN2 (0.42) LMNAALDH1A1RAB9ASMN1; SMN2HPGD
SCHEMBL20921347 0.74 SMN1; SMN2 (0.42) LMNAALDH1A1RAB9ASMN1; SMN2HPGD
SCHEMBL9358852 0.74 PDK2 (0.39) LMNAALDH1A1RAB9ASMN1; SMN2HPGD
SCHEMBL3075428 0.74 EHMT2 (0.56) LMNAEHMT2EHMT1APOBEC3GALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8268814-B2 Substituted sulfonamide compounds GRUENENTHAL GMBH (DE) 2012-09-18 US disclosed
US-20090275558-A1 SUBSTITUTED SULFONAMIDE COMPOUNDS GRUENENTHAL GMBH (DE) 2009-11-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275558-A1 SUBSTITUTED SULFONAMIDE COMPOUNDS BDKRB2, BDKRB1, TRPV1 LMNA 2606/4885EHMT2 4806/4885EHMT1 4545/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.